Transitions Clinic Network: Post Incarceration Addiction Treatment,

Status Recruiting

Clinical Trial Summary

TCN PATHS will recruit an anticipated 400 participants who are prescribed MOUD who are released from detention facilities. Each individual will be randomized to either 1) standard primary care (SPC) or 2) a Transitions Clinic Network (TCN) program primary care. Participants will be followed for a year and complete surveys at baseline and at month 1, 3, 6, 9, and 12. At each of these points research staff will confirm MOUD status. Urine drug screenings will be completed at baseline, month 1, 6, and 12 if the participant is not incarcerated. When possible, research staff will collect electronic health records.

Clinical Trial Description

Purpose: The overall objective of this study is to assess whether the Transitions Clinic Network (TCN) program, which provides enhanced primary care and opioid use disorder (OUD) treatment for people recently released from incarceration, improves measures in the opioid treatment cascade compared to referral to standard primary care. Participants: An anticipated 400 individuals currently receiving medications for OUD released from eight local jails (Durham, NC; Minneapolis, MN; Bronx, NY; Bridgeport and Niantic, CT; and Bayamón and Ponce, Puerto Rico) Procedures: This is a hybrid type I effectiveness-implementation trial will randomize an anticipated 400 participants to one of two treatment conditions: TCN or standard primary care. People will complete the enrollment process while in jail (recruitment, screening, consent, baseline assessments, and randomization). Due to COVID-19 restrictions some jails are limiting researcher assess to people and some of our sites may enroll participants once they are released, this is referred to as a community enrollment. Post participants will meet with research assistants for a structured interview and urine toxicology screening at 1, 6, and 12 months, and a phone interview at months 3 and 9. 120 people will be selected to participate in Intensive Longitudinal Assessment (ILA) to access both the acceptability and appropriateness of the TCN intervention and the multi-level facilitators and barriers of OUD treatment engagement in the first 30 days following release from incarceration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04309565
Study type	Interventional
Source	Yale University
Contact	Emily Wang, MD
Phone	203-737-7624
Email	emily.wang@yale.edu
Status	Recruiting
Phase	N/A
Start date	April 21, 2021
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04336293` - sTMS for Substance Use-disordered Veterans	N/A
Completed	`NCT01188421` - Medications Development for Drug Abuse Disorders	Phase 1/Phase 2
Completed	`NCT00499746` - The Discriminative Effects of Tramadol in Humans	Phase 1/Phase 2
Not yet recruiting	`NCT05611749` - Duloxetine Impact on Postoperative Pain Control and Outcomes	Phase 2
Recruiting	`NCT04325659` - An Innovative Intervention for OUD Treatment	Phase 2/Phase 3
Completed	`NCT03685162` - Observational Study to Evaluate Levomethadone Safety and Effectiveness in Subjects Under Opioid Maintenance Treatment
Recruiting	`NCT04239235` - Integrating Support Persons Into Recovery	N/A
Not yet recruiting	`NCT03394911` - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction	Phase 3
Not yet recruiting	`NCT02282072` - PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction	Phase 0
Not yet recruiting	`NCT01008072` - Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.	N/A
Completed	`NCT02696096` - Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence	Phase 3
Recruiting	`NCT05299515` - Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence	N/A
Completed	`NCT01590251` - Yoga for Pain and Opioid Dependence	Phase 1/Phase 2
Completed	`NCT01873989` - Testosterone Replacement for Male Opioid Agonist Maintained Patients	Phase 1/Phase 2
Active, not recruiting	`NCT02866266` - ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning	N/A
Enrolling by invitation	`NCT02871232` - Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support — TCN-PATHS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms